Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.

November 10, 2022

Consolidated Financial Results
for the Six Months Ended September 30, 2022
(Under Japanese GAAP)
Company name:
Listing:
Securities code:
URL:
Representative:
Inquiries:

Takara Bio Inc.
Tokyo Stock Exchange4974
https://www.takara-bio.co.jp
Koichi Nakao, President & CEO

Takuya Kakemi, Executive Officer, in charge of PR & IR Department

Telephone:+81-77-565-6970
Scheduled date to file quarterly securities report:
November 11, 2022
Scheduled date to commence dividend payments:
Preparation of supplementary material on quarterly financial results: Yes
Holding of quarterly financial results briefing:
Yes(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended September 30, 2022 (from April 1, 2022 to September
30, 2022)(1) Consolidated operating results (cumulative)
Net sales
Six months ended(Percentages indicate year-on-year changes.)

Operating profit

Net income attributableto owners of the parent

Ordinary profit

Millions of yen%

Millions of yen%

Millions of yen%

Millions of yen%

Sep. 30, 2022

32,587

3.3

10,870(22.9)

10,955(23.1)

8,538(14.7)

Sep. 30, 2021

31,551

81.4

14,105277.5

14,241

272.8

10,009340.1

Note: Comprehensive income

For the six months ended Sep. 30, 2022:
For the six months ended Sep. 30, 2021:¥14,858 million; 19.9%¥12,390 million; 670.4%

Fully diluted net income
per share

Net income per share
Six months ended

Yen

Yen

Sep. 30, 2022

70.91

Sep. 30, 2021

83.12

-

(2) Consolidated financial position
Total assets
As of

Net assets

Equity-to-asset ratio

Net assets per share

Millions of yen

Millions of yen%

yen

Sep. 30, 2022

120,023

106,94988.9

886.08Mar. 31, 2022

115,71296,06482.9

796.18Reference:

EquityAs of Sep. 30, 2022:
As of Mar. 31, 2022:¥106,697 million¥95,873 million

2. Cash dividends
Annual dividends per shareFirst quarter-end

Second quarter-end

Third quarter-end

Yen

Yen

Yen

Yen

Yen

-

0.00

-

33.00

33.00

-

0.00
-

40.00

40.00

Fiscal year ended
Mar. 31, 2022
Fiscal year ending
Mar. 31, 2023
Fiscal year ending
Mar. 31, 2023
(Forecast)Fiscal year-end

Total

Note: Revisions to the forecast of cash dividends most recently announced: Yes

3. Consolidated financial forecasts for the fiscal year ending March 31, 2023 (April. 1, 2022 – March. 31, 2023)(Percentages indicate year-on-year changes.)

Net sales
Millions of yen

Full year
Note:*

77,800Operating profit%

Millions ofyen%

19,000 (34.3)

19,100(32.9)% Millions of yen

14.9

Net income
attributable toowners of the parent

Ordinary profit

Millions ofyen

Net income per
share

%

yen

13,800 (30.5)

114.60

Revisions to the financial forecast since the most recent announced: Yes

Notes(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change
in scope of consolidation): None
Newly included: - companies (Company name)
Excluded:- companies (Company name)(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements:
None(3) Changes in accounting policies, changes in accounting estimates, and restatement(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None(ii) Changes in accounting policies due to other reasons: None(iii) Changes in accounting estimates: None(iv) Restatement: None
(4) Number of issued shares (common shares)(i)

Total number of issued shares at the end of the period (including treasury shares)
As of Sep. 30, 2022

120,415,600 shares

As of Mar. 31, 2022

120,415,600 shares(ii) Number of treasury shares at the end of the period
As of Sep. 30, 2022-

shares

As of Mar. 31, 2022-

shares(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal
year)
Six months ended Sep. 30, 2022

120,415,600 shares

Six months ended Sep. 30, 2021

120,415,600 shares* Quarterly financial results reports are exempt from quarterly review conducted by certified public accountants oran audit corporation.
* Proper use of financial forecasts, and other special matters(Special note regarding forward-looking statements)
The forward-looking statements, including financial forecasts, contained in this document are determined by the Takara

Bio Inc. (the “Company”) based on information currently available to the Company and include a number of
uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For
information regarding the above, please refer to “1. Overview of Financial Results for the six months ended September
30, 2022 (4) Future Outlook on page 2 of the attached document.

Contents of the attached document
1. Overview of Financial Results for the six months ended September 30, 2022........................................................................
(1) Overview of Financial Results............................................................................................................................................
(2) Overview of Financial Position...........................................................................................................................................
(3) Overview of Cash Flows…………………………………………………………….…………………………….……...
(4) Future Outlook....................................................................................................................................................................
2. Consolidated Quarterly Financial Statements and Primary Notes...........................................................................................
(1) Consolidated Quarterly Balance Sheets..............................................................................................................................
(2) Consolidated Quarterly Statements of Profit or Loss and Comprehensive Income..................................................................
(Consolidated Quarterly Statements of Profit or Loss)..................................................................................................
(Consolidated Quarterly Statements of Comprehensive Income)..................................................................................
(3) Consolidated Quarterly Statements of Cash Flows.............................................................................................................
(4) Notes to Consolidated Quarterly Financial Statements.......................................................................................................
(Notes on Premise of Going Concern)..............................................................................................................................
(Notes in case of Changes in Marked Amount of Shareholders’ Equity).........................................................................
(Additional Information)...................................................................................................................................................
(Significant Subsequent Events).......................................................................................................................................
3. Supplementary Information......................................................................................................................................................
(1) Trends in Key Indicators for Business Management...........................................................................................................
(2) Comparative Consolidated Statement of Income................................................................................................................
(3) Comparative Statement of Income Relating to Consolidated Financial Forecasts.............................................................

-1-

2
2
2
2
3
4
4
6
6
7
8
9
9
9
9
9
10
10
11
12

1. Overview of Financial Results for the six months ended September 30, 2022
(1) Overview of Financial Results
The outlook for the global economy in the fiscal year under review is uncertain due to the impact of the new Coronavirus disease(COVID-19), the prolonged trade friction between the U.S. and China, and Russia’s invasion of Ukraine.
Under these circumstances, Takara Bio Group is promoting initiatives to advance the development of fundamental biologics
development technologies and become a biologics development company that continuously creates new modalities through Reagentsand Instruments and CDMO business under the six-year Long-Term Management Plan FY2026, which ends in fiscal 2026, and thethree-year Medium-Term Management Plan FY2023, which ends in fiscal 2023 1. In addition, the Group worked aggressively to ensurea stable supply of testing-related products for the new Coronavirus and to establish a manufacturing system for regenerative medicine
and other products.
In the fiscal year under review, although sales of Instruments and CDMO decreased year on year, sales of Reagents and Gene Therapy
increased year on year. In particular, Reagents for general research increased, while Reagents related to the new Coronavirus test
increased due to the impact of the 7th wave of COVID-19 in Japan. As a result, net sales increased to ¥32,587 million (up 3.3% year
on year). Cost of sales increased to ¥10,562 million (up 31.1% year on year) due to changes in the sales mix, gross profit decreasedto ¥22,025 million (down 6.3% year on year). Selling, general and administrative (SG&A) expenses were ¥11,154 million (up 18.8%
year on year), mainly due to an increase in personnel expenses and R&D expenses. Operating profit was ¥10,870 million (down
22.9% year on year).
As a result of the decrease in operating profit, ordinary profit decreased to ¥10,955 million (down 23.1% year on year), income
before income taxes and others decreased to ¥11,831 million (down 16.7% year on year), and net income attributable to owners of theparent decreased to ¥8,538 million (down 14.7% year on year).
From the first quarter of the fiscal year under review, due to a review of management classifications, sales of reagents and otherproducts of GMP grade (for the manufacture of regenerative medicine products), which were previously included in Reagents, areincluded in Gene Therapy. As a result, net sales for the second quarter of the previous fiscal year have been reclassified based on the
new classification. In the second quarter of the previous fiscal year, ¥977 million, which was included in Reagents, has been
reclassified as Gene Therapy.
Since our group is a single segment, the disclosure by segment is omitted.
(2) Overview of Financial Position
Total assets at the end of the second quarter under review were ¥120,023 million, it was a increase of ¥4,310 million from the end of
the previous fiscal year. This was mainly due to increases of ¥3,332 million in cash and deposits and ¥2.573 million in property, plantand equipment mainly owing to the acquisition of our manufacturing facilities, despite a decrease of ¥1,453 million in note andaccounts receivable-trade.
Total liabilities at the end of the second quarter under review were ¥13,073 million, it was a decrease of ¥6,574 million from theend of the previous fiscal year. This was mainly due to decreases of ¥3,341 million in accrued income taxes and ¥3,326 million inother current liabilities.
Total net assets at the end of the second quarter under review were ¥106,949 million, an increase of ¥10,884 million from the endof the previous fiscal year. This was mainly due to increases of ¥4,564 million in retained earnings and ¥6,238 million in foreign
currency translation adjustment due to the yen’s depreciation.
(3) Overview of Cash FlowsNet cash provided by operating activities amounted to ¥8,672 million, a decrease of ¥1,242 million from the previous fiscal year.
This was mainly due to balance between cash inflow from profit before income taxes and others of ¥11,831 million, decrease intrade receivables-trade of ¥2,055 million, depreciation and amortization of ¥1,962 million and cash outflow from income taxes
paid of ¥6,093 million.
Net cash used in investing activities was minus ¥7,518 million, a decrease of ¥3,168 million from the previous fiscal year. Thiswas mainly due to payments into time deposits of ¥5,527 million, purchase of property, plant and equipment and intangible assetsof ¥3,076 million, and proceeds from withdrawal of time deposits of ¥792 million.
Net cash used in financing activities amounted to ¥4,034 million, an increase of ¥2,042 million from the previous fiscal year,
mainly due to cash dividends paid of ¥3,965 million.
As a result of the above, the balance of cash and cash equivalents at the end of the second quarter under review, including theeffect of exchange rate changes on cash and cash equivalents, decreased by ¥1,554 million from the end of the previous fiscal yearto ¥20,606 million

1

FY2026 and FY2023 refer to the fiscal year ending March 31, 2026 and 2023, respectively.

-2-(4) Future Outlook
The financial forecast and dividend forecast announced in the financial results summary on May 12, 2022 have been revised. For
details, please refer to “Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (Dividend
Increase)” announced today (November 10, 2022).
For comparison of the revised consolidated financial forecasts with previous fiscal year’s results and the previous financial
forecasts, please refer to the “Comparative Statement of Income Relating to Consolidated Financial Forecasts” on page 12.

-3-2. Consolidated Quarterly Financial Statements and Primary Notes(1) Consolidated Quarterly Balance Sheets(Millions of yen)

As of Mar. 31, 2022
AssetsCurrent asset
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation

Machinery, equipment and vehicles, net

Tools, furniture and fixtures
Accumulated depreciation
Tools, furniture and fixtures, net
LandConstruction in progress
Others
Accumulated depreciation
Others, net
Total Property, plant and equipment
Intangible assets
Goodwill
Other
Total intangible assets
Investments and other assets
Investments and other assets
Total investments and other assets
Total non-current assets
Total assets-4-

As of Sep. 30, 2022

23,633
17,845
18,966
1,361
3,738
2,637
(40)
68,141

26,965
16,391
18,591
1,452
4,074
1,939
(43)
69,37023,553(5,937)
17,615
7,626(4,147)
3,479
9,530(5,516)
4,014
8,413
1,519
1,642
(287)
1,355
36,39525,580(6,753)
18,826
8,175(4,726)
3,448
10,078(6,089)
3,989
8,747
2,570
1,752
(366)
1,385
38,968

6,309
2,850
9,159

7,186
2,844
10,031

2,015
2,015
47,571
115,712

1,651
1,651
50,652120,023

(Millions of yen)
As of Mar. 31, 2022
Liabilities
Current liabilities
Notes and accounts payable-trade
Accrued income taxes
Provision
Other
Total current liabilities
Non-current liabilities
Retirement benefit liabilities
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders’ equity
Shareholders’ equity
Capital surplus
Retained earnings
Total shareholders' equity
Accumulated other comprehensive income
Foreign currency translation adjustment
Cumulative remeasurements of retirement
benefit
Total accumulated other comprehensive
incomeNon-controlling interests
Total net assets
Total liabilities and net assets-5-

As of Sep. 30, 2022

1,959
5,498
923
8,999
17,380

1,686
2,156
973
5,672
10,488

788
1,478
2,266
19,647

788
1,796
2,585
13,073

14,96532,89345,00992,868

14,96532,89349,57397,433

3,208

9,447

(204)

(182)

3,004

9,264

191
96,064
115,712251
106,949
120,023

(2) Consolidated Quarterly Statements of Profit or Loss and Comprehensive Income(Consolidated Quarterly Statements of Profit or Loss)(Six Months Ended Sep. 30, 2022)

Net sales
Cost of sales
Gross profit
SG&A expenses
Employees' salaries and bonuses
Retirement benefit expenses
R&D expenses
Provision of allowance
Other
Total SG&A expenses
Operating profit
Non-operating income
Interest income
Foreign exchange gains
Rent income from real estate
Other
Total non-operating income
Non-operating expense
Interest expenses
Foreign exchange loss
Rent expenses on real estate
Other
Total non-operating expenses
Ordinary profit
Extraordinary gains
Gain on sale of fixed assets
Insurance received
National subsidies
Total extraordinary profit
Extraordinary losses
Loss of sales on non-current assets
Asset shrinkage losses
OthersTotal extraordinary losses
Profit before income taxes and others
Income taxes-current
Income taxes-deferred
Total income taxes
Net income
Net income attributable to non-controlling interest
Net income attributable to owners of the parent(Millions of yen)Six months ended
Sep. 30, 2021
31,551
8,056
23,495Six months ended
Sep. 30, 2022
32,587
10,562
22,025

2,411
115
2,659
451
3,752
9,389
14,105

2,758
122
3,853
433
3,986
11,154
10,870

65
36
65
11
179

65
72
33
170

11
29
1
43
14,241

12
38
32
1
85
10,955

0
1,188
1,188

250
652
902

38
1,188
1,227
14,203
4,401
(253)
4,148
10,05445
10,00912
14
27
11,831
2,538
721
3,259
8,572
33
8,538

-6-

(Consolidated Quarterly Statements of Comprehensive Income)(Six Months Ended Sep. 30, 2022)(Millions of yen)Six months ended
Sep. 30, 2021
Net income
Other comprehensive income
Foreign currency translation adjustment
Remeasurements of retirement benefit
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to:
Owners of the parent
Non-controlling interest-7-

Six months ended
Sep. 30, 2022

10,054

8,572

2,312
23
2,335
12,390

6,264
21
6,286
14,85812,33753

14,79859

(3) Consolidated Quarterly Statements of Cash Flows(Millions of yen)Six months ended
Sep. 30, 2021

Net cash provided by (used in) operating activities
Profit before income taxes and others
Depreciation and amortization
Depreciation and amortization on other
Amortization of goodwill
Increase (decrease) in allowance for doubtful
accounts
Increase (decrease) in other provision
Increase (decrease) in retirement benefit liabilities
Interest income
Interest expenses
Insurance claim income
Loss (gain) on sale and retirement of fixed assets
Decrease (increase) in trade receivables-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payabletrade
Increase (decrease) in other current liabilities
Other
SubtotalInterest and dividend income received
Income expenses paid
Income taxes paid
Proceeds from insurance income
Subsidies received
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Payments into time deposits
Purchase of property, plant and equipment andintangible assets
Proceeds from sales of property, plant and equipment
and intangible assets
Purchase of other depreciable assets
Subsidies received
Other
Net cash provided by (used in) investing activities
Net cash provided by (used in) financing activities
Dividends paid
Repayments of lease obligations
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash
equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period-8-

Six months ended
Sep. 30, 2022

14,203
1,670
46
245

11,831
1,962
35
280

(3)

(20)

72
(7)
(65)
11
38
(766)
(1,076)

(22)
(1)
(65)
12
(652)
(238)
2,055
960

(621)

(615)

(834)
119
13,03376(11)(3,854)671
9,914(1,965)513
14,07055(13)(6,093)652
8,672(10,340)
1,702(5,527)792(5,367)(3,076)

0

394

(28)
3,349
(1)
(10,686)(111)
10(7,518)(1,922)(69)(1,992)(3,965)(69)(4,034)

568

1,325

(2,195)23,308
21,113(1,554)
22,16020,606

(4) Notes to Consolidated Quarterly Financial Statements(Notes on Premise of Going Concern)
No items to report.
(Notes in case of Changes in Marked Amount of Shareholders’ Equity)
No item to report.
(Additional Information)(Accounting Estimates for the Impact of the COVID-19)
No material changes have been made to the assumptions used in the previous fiscal year, including the future
spread and timing of convergence of the COVID-19.
(Significant Subsequent Events)(Termination of the Agreement)
At a meeting of the Board of Directors held on November 10, 2022, the Company resolved to terminate theagreement for the co-development and sales of NY-ESO-1 siTCR with Otsuka Pharmaceutical Co., Ltd. (the“agreement”), and the agreement was terminated on the same date upon mutual consent with Otsuka
Pharmaceutical Co., Ltd. (Otsuka).
(1) Reason for the agreement termination
In collaboration with Otsuka, the Company had been developing NY-ESO-1 siTCRTM gene therapy product(the “product”) in Japan and preparing for an application for marketing authorization. After a comprehensive
review of policies and strategies related to the product by both companies, the Company and Otsuka agreed
to terminate the agreement. This judgement is not due to any problem with the efficacy and safety of the
product.
(2) Name of the counterparty to the agreement
Otsuka Pharmaceutical Co., Ltd.
(3) Date of the agreement termination
November 10, 2022
(4) Details of the agreement
 The Company and Otsuka co-develop the product in Japan.
 The Company grants Otsuka exclusive rights to market the product domestically for all indications andfirst refusal rights in nine Asian countries. The Company receive an upfront payment, milestone payments
based on the progress of development. After the launch, the Company will receive lump-sum payments
based on the achievement of certain running royalties and sales targets linked to net sales.
 The Company retains the rights to manufacture the product for clinical trials and the further
commercialization and supply Otsuka on a chargeable basis.
(5) Significant impact of the termination on business activities
The technology, intellectual property and other rights related to the product licensed to Otsuka upon
termination of the agreement will be returned to the Company. The milestone payments, lump-sum payments
and the sales revenues on the further commercial supply will not occur.

-9-3. Supplemental Information(1)Trends in Key Indicators for Business Management
1) Cash FlowsSix months ended
Sep. 30, 2021

(Apr. 1, 2021 – Sep. 30, 2021)

Cash flow from operating activities
Cash flow from investing activities
Cash flow from financing activities

9,914(10,686)(1,992)Six months ended
Sep. 30, 2022

(Apr. 1, 2022 – Sep. 30, 2022) (Apr. 1, 2021 – Mar. 31, 2022)

8,672(7,518)(4,034)2) Sales Breakdown by Region
Six months ended
Sep. 30, 2021

Japan
United States
China
Asia excluding Japan and China
EuropeOthers
Total(Apr. 1, 2021 – Sep. 30, 2021)

15,439
4,548
5,472
3,450
2,526
113
31,551- 10 -(Millions of yen)
Year ended
Mar. 31, 2022

Six months ended
Sep. 30, 2022

6,985
(7,071)(2,070)(Millions of yen)
Year ended
Mar. 31, 2022

(Apr. 1, 2022 – Sep. 30, 2022) (Apr. 1, 2021 – Mar. 31, 2022)

16,298
6,263
5,388
1,860
2,643
132
32,58734,076
10,186
11,908
6,614
4,668
244
67,699(2) Comparative Consolidated Statement of Income(Net sales)
Reagents
Instruments
CDMO
Gene Therapy
Total net sales(Operating profit and Loss)
Net sales
Cost of sales
Gross profit
SG & A expenses
Transportation expenses
Advertising expenses
Promotion expenses
R&D expenses
Administrative expense, other

Enterprise taxes (external
standards taxation)

Operating profit(Non-operating income andExpenses)Non-operating income
Non-operating expenses
Ordinary profit(Extraordinary income & Losses)

Extraordinary income
Extraordinary losses
Income before income
taxes and others
Income taxes
Net income

Net income (loss) attributable tonon-controlling interests

Net income attributableto owners of the parent
Depreciation andamortization (Property,
plant and equipment andintangible assets)
Amortization of goodwill

Six months ended
Sep. 30, 2021

(Rounded down to one million yen)Six months ended
Y/Y
Y/Y
Sep. 30, 2022
changeratio

24,988
712
4,732
1,117
31,551

27,565
694
3,183
1,144
32,5872,576(17)(1,548)
26
1,035

10.3%
(2.5%)(32.7%)
2.3%
3.3%

31,551
8,056
23,495
9,389
406
28
305
2,659
5,714

32,587
10,562
22,025
11,154
330
21
306
3,853
6,412

1,035
2,505
(1,470)
1,764
(75)
(6)
1
1,193
698

3.3%
31.1%
(6.3%)
18.8%(18.6%)(23.0%)
0.3%
44.9%
12.2%

275

229

(45)

(16.7%)

14,105

10,870(3,234)(22.9%)

179
43
14,241

170
85
10,955(8)
42(3,285)(4.8%)
97.4%(23.1%)

1,188
1,227

902
27

(286)
(1,200)(24.1%)(97.8%)

14,203

11,831(2,371)(16.7%)

4,148
10,054

3,259
8,572

(888)
(1,482)(21.4%)(14.7%)

45

33

(12)

(26.5%)

10,0098,538(1,470)(14.7%)

1,670

1,962

291

17.4%

245

280

34

14.2%

※ The sales of GMP-grade reagents included in "Reagents" until the year ended of March 31, 2022 have been included in"Gene Therapy " since the year ending March 31, 2023. The result for the year ended Mar. 31, 2022 in this table have been
reclassified to reflect these changes.

- 11 -

(3) Comparative Statement of Income Relating to Consolidated Financial Forecasts(Rounded down to one million yen)
Year
Year ending
ended
Previous Previous
Mar. 31, 2023
Y/Y
Y/Y
Mar. 31,
forecast
forecast
ChangeRatio
Previous Current
2022
ChangeRatio
forecast
forecast
Actual(Net sales)
Reagents
52,47941,01065,106
12,62624.1%
24,095
58.8%
Instruments
1,518
1,471
1,716
197
13.0%
244
16.6%
CDMO
11,426
10,212
8,356(3,070)(26.9%)(1,855)(18.2%)
Gene Therapy
2,275
2,606
2,621
346
15.2%
15
0.6%
Total Net Sales
67,69955,30077,80010,10014.9%
22,50040.7%(Operating profit and Loss)
67,69955,30077,80010,10014.9%
22,50040.7%
Net sales
Cost of sales
18,48817,44434,06815,58084.3%
16,624
95.3%
Gross profit
49,21137,85543,731(5,480)(11.1%)
5,875
15.5%
SG & A expenses
20,30922,85524,731
4,421
21.8%
1,875
8.2%
Transportation expenses
755
748
667
(88)
(11.7%)(81)(10.9%)
Advertising expenses
58
91
51
(6)
(11.8%)(39)(43.8%)
Promotion expenses
683
899
729
45
6.7%
(169)
(18.9%)
R&D expenses
6,109
7,820
8,713
2,604
42.6%
893
11.4%
Administrative expenses,
12,153
12,877
14,118
1,964
16.2%
1,241
9.6%
other
Enterprise taxes(external standards
548
418
450
(97)
(17.8%)
31
7.6%
taxation)
28,902
15,00019,000(9,902)(34.3%)
4,000
26.7%
Operating profit(Non-operating income andExpenses)Non-operating income
357
211
244
(113)
(31.7%)
32
15.5%
Non-operating expenses
800
111
144
(655)
(82.0%)
32
29.4%
28,45915,10019,100(9,359)(32.9%)
4,000
26.5%
Ordinary profit(Extraordinary gains &Losses)Extraordinary gains
4,476
250
902
(3,573)(79.8%)
652
260.9%
Extraordinary losses
5,403
55
75
(5,328)(98.6%)
19
35.2%
Income before income
27,532
15,29419,927(7,605)(27.6%)
4,632
30.3%
taxes and others
Income taxes
7,624
4,648
6,102
(1,522)(20.0%)
1,453
31.3%
Net income
19,908
10,645
13,825(6,082)(30.6%)
3,179
29.9%
Net income (loss)
attributable to non58
45
25
(33)
(56.9%)(20)(45.1%)
controlling interests
Net income attributable
19,84910,60013,800(6,049)(30.5%)
3,200
30.2%
to owners of parent
Depreciation andamortization (Property,
plant and equipment andintangible assets)
Amortization of goodwill

3,554

4,282

4,207

652

18.3%

(75)

(1.8%)

500

514

599

99

19.9%

85

16.6%

※ The sales of GMP-grade reagents included in "Reagents" until the year ended of March 31, 2022 have been included in "Gene
Therapy " since the year ending March 31, 2023. The results for the year ended Mar. 31, 2022 in this table have been reclassified toreflect these changes.

- 12 -